open access

Vol 13, No 4 (2016)
Review paper
Get Citation

Alzheimer’s disease — new strategies of treatment

Rafał Młynarczyk, Benjamin Bochon, Alicja Piontek, Łukasz Kunert, Jarosław Sobiś, Piotr W. Gorczyca
Psychiatria 2016;13(4):210-214.

open access

Vol 13, No 4 (2016)
Prace poglądowe - nadesłane

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease, which is the main cause of appearing dementia in the elderly. The reason of Alzheimer’s disease is multifactorial. However, it is considered that the main mechanism of its development is the accumulation of beta-amyloid and phosphorylated tau protein in brain tissue. For the time being, AD is an incurable disease. The pharmacological treatment only relieves the symptoms. Therefore, the researchers are working on the invention of causal treatment. The current studies are focused on immunotherapy and disposal of excess beta-amyloid from the organism.

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disease, which is the main cause of appearing dementia in the elderly. The reason of Alzheimer’s disease is multifactorial. However, it is considered that the main mechanism of its development is the accumulation of beta-amyloid and phosphorylated tau protein in brain tissue. For the time being, AD is an incurable disease. The pharmacological treatment only relieves the symptoms. Therefore, the researchers are working on the invention of causal treatment. The current studies are focused on immunotherapy and disposal of excess beta-amyloid from the organism.

Get Citation

Keywords

Alzheimer’s disease, dementia, beta-amyloid, tau protein, immunotherapy

About this article
Title

Alzheimer’s disease — new strategies of treatment

Journal

Psychiatria (Psychiatry)

Issue

Vol 13, No 4 (2016)

Article type

Review paper

Pages

210-214

Bibliographic record

Psychiatria 2016;13(4):210-214.

Keywords

Alzheimer’s disease
dementia
beta-amyloid
tau protein
immunotherapy

Authors

Rafał Młynarczyk
Benjamin Bochon
Alicja Piontek
Łukasz Kunert
Jarosław Sobiś
Piotr W. Gorczyca

References (45)
  1. Gelinas DS, DaSilva K, Fenili D, et al. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A. 2004; 101 Suppl 2: 14657–14662.
  2. Folch J, Petrov D, Ettcheto M, et al. Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. Neural Plast. 2016; 2016: 8501693.
  3. Korolev IO. Alzheimer’s disease: a clinical and basic science review. Medical Student Research Journal . 2014; 4: 24–33.
  4. Fu HJ, Liu B, Frost JL, et al. Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets. 2010; 9(2): 197–206.
  5. Tabira T. Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. Tohoku J Exp Med. 2010; 220(2): 95–106.
  6. Cribbs DH. Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets. 2010; 9(2): 207–216.
  7. Wilcock DM, Colton CA. Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis. 2008; 15(4): 555–569.
  8. Valera E, Spencer B, Masliah E. Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics. 2016; 13(1): 179–189.
  9. Farlow MR, Andreasen N, Riviere ME, et al. Long-term treatment with active Aβ immunotherapy with CAD106 in mild Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1): 23.
  10. Andreasen N, Simeoni M, Ostlund H, et al. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study. PLoS One. 2015; 10(3): e0098153.
  11. Swerdlow RH, Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses. 2004; 63(1): 8–20.
  12. Doody RS, Gavrilova SI, Sano M, et al. dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372(9634): 207–215.
  13. Pieper AA, Xie S, Capota E, et al. Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010; 142(1): 39–51.
  14. Steele JW, Lachenmayer ML, Ju S, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry. 2013; 18(8): 889–897.
  15. Yamashita M, Nonaka T, Arai T, et al. Methylene blue and dimebon inhibit aggregation of TDP-43 in cellular models. FEBS Lett. 2009; 583(14): 2419–2424.
  16. Doody RS, Gavrilova SI, Sano M, et al. dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008; 372(9634): 207–215.
  17. Doody R, Winblad B, Cummings J, et al. Dimebon in Alzheimer's disease: Summary and contrast of three efficacy trials. Alzheimer's & Dementia. 2012; 8 (4 supl. 1): P456.
  18. Chau S, Herrmann N, Ruthirakuhan MT, et al. Latrepirdine for Alzheimer's disease. Cochrane Database Syst Rev. 2015(4): CD009524.
  19. Cano-Cuenca N, Solís-García del Pozo JE, Jordán J. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J Alzheimers Dis. 2014; 38(1): 155–164.
  20. Burns J, Yokota T, Ashihara H, et al. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002; 50(11): 3337–3340.
  21. Rimando AM, Kalt W, Magee JB, et al. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J Agric Food Chem. 2004; 52(15): 4713–4719.
  22. Sanders TH, McMichael RW, Hendrix KW. Occurrence of resveratrol in edible peanuts. J Agric Food Chem. 2000; 48(4): 1243–1246.
  23. Orgogozo JM, Dartigues JF, Lafont S, et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev Neurol (Paris). 1997; 153(3): 185–192.
  24. Krikorian R, Nash TA, Shidler MD, et al. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br J Nutr. 2010; 103(5): 730–734.
  25. Abraham J, Johnson RW. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res. 2009; 12(6): 445–453.
  26. Turner RS, Thomas RG, Craft S, et al. Alzheimer's Disease Cooperative Study. A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology. 2015; 85(16): 1383–1391.
  27. Abd El-Mohsen M, Bayele H, Kuhnle G, et al. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br J Nutr. 2006; 96(1): 62–70.
  28. Ho DJ, Calingasan NY, Wille E, et al. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp Neurol. 2010; 225(1): 74–84.
  29. Whitfield JF. The road to LOAD: late-onset Alzheimer's disease and a possible way to block it. Expert Opin Ther Targets. 2007; 11(10): 1257–1260.
  30. Li G, Larson EB, Sonnen JA, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007; 69(9): 878–885.
  31. Reed B, Villeneuve S, Mack W, et al. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol. 2014; 71(2): 195–200.
  32. Williams PT. Lower risk of Alzheimer's disease mortality with exercise, statin, and fruit intake. J Alzheimers Dis. 2015; 44(4): 1121–1129.
  33. Lin FC, Chuang YS, Hsieh HM, et al. Early Statin Use and the Progression of Alzheimer Disease: A Total Population-Based Case-Control Study. Medicine (Baltimore). 2015; 94(47): e2143.
  34. Tamaoka A. [Dyslipidemia and Dementia]. Brain Nerve. 2016; 68(7): 737–742.
  35. Doody RS, Raman R, Sperling RA, et al. Alzheimer’s Disease Cooperative Study. Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's disease. Alzheimers Res Ther. 2015; 7(1): 36.
  36. Green RC, Schneider LS, Amato DA, et al. Tarenflurbil Phase 3 Study Group. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009; 302(23): 2557–2564.
  37. Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis. 2015; 44(2): 705–720.
  38. Bulic B, Pickhardt M, Schmidt B, et al. Development of tau aggregation inhibitors for Alzheimer's disease. Angew Chem Int Ed Engl. 2009; 48(10): 1740–1752.
  39. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology. 2009; 73(10): 768–774.
  40. Holmes C, Cunningham C, Zotova E, et al. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology. 2011; 77(3): 212–218.
  41. Butchart J, Brook L, Hopkins V, et al. Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. Neurology. 2015; 84(21): 2161–2168.
  42. Hirsh S, Huber L, Stein R, et al. Open label, crossover, pilot study to assess the efficacy and safety of perispinal administration of etanercept (Enbrel ® ) in combination with nutritional supplements versus nutritional supplements alone in subjects with mild to moderate Alzheimer’s disease receiving standard care. FASEB J . 2016; 30: lb296.
  43. Ohyagi Y. Apomorphine: A Novel Efficacy for Alzheimer?s Disease and Its Mechanisms. Journal of Alzheimer’s Disease & Parkinsonism. 2012; 2(4): e122.
  44. Martin C, Solís L, Concha MI, et al. [Herpes simplex virus type 1 as risk factor associated to Alzheimer disease]. Rev Med Chil. 2011; 139(6): 779–786.
  45. Wozniak MA, Mee AP, Itzhaki RF. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. J Pathol. 2009; 217(1): 131–138.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl